FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin

Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers and not where in the body the tumor originated.

Read More

FDA Approves Fourth Immune Checkpoint Inhibitor for Bladder Cancer

This time last year there were no immune checkpoint inhibitors approved by the U.S. Food and Drug Administration (FDA) for treating the most common form of bladder cancer—urothelial carcinoma. The approval of avelumab (Bavencio) earlier this week means there are now four of these revolutionary immunotherapeutics in the armamentarium.

Read More

FDA Approves Fourth ALK Inhibitor for Lung Cancer

Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the molecularly targeted therapeutic brigatinib (Alunbrig) for treating certain patients with metastatic non–small cell lung cancer (NSCLC).

Read More

New Guidelines Suggest Individualized Approach to Prostate Cancer Screening

The U.S. Preventive Services Task Force (USPSTF) released draft recommendations April 11 suggesting that doctors inform men ages 55 to 69 of the potential benefits and harms of prostate-specific antigen (PSA) blood testing to screen for prostate cancer. The draft says the decision to be screened is an individual one that should be made after consulting with a physician.

Read More

AACR Annual Meeting 2017: Most Merkel Cell Carcinoma Responses to the Newly FDA-Approved Avelumab Expected to Last More than a Year

T cells and antibodies

On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma. The treatment, the immunotherapeutic avelumab (Bavencio), was approved based on data from the JAVELIN Merkel 200 phase II clinical trial.

Read More

AACR Annual Meeting 2017: If You Can’t Drug It, Degrade It – A Protein Degradation Technology to Tackle Undruggable Oncoproteins

Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers in the field of oncology drug development.

Read More